Compare Global X Data Center & Digital Infra ETF (DTCR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Data Center & Digital Infra ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Global X Data Center & Digital Infra ETF trades at $26.08 (market cap $2.11B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.6× Global X Data Center & Digital Infra ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Data Center & Digital Infra ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 17 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| DTCR | SYRE | |
|---|---|---|
Market Cap | $2.11B | $7.52B |
Volume | 655,653 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $108.92 |
52-Week Low | $19.73 | $22.18 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DTCR trades at $27.33, down 1.44% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Recent news highlights DTCR's position as a key ETF for AI infrastructure exposure, with coverage emphasizing its blend of real estate stability and growth from digital infrastructure sectors. The ETF has gained attention as a picks-and-shovels play in the AI boom.
The outlook for DTCR appears favorable given sustained AI infrastructure investment, though risks include sector volatility and interest rate sensitivity. Analyst sentiment remains positive with buy recommendations citing long-term growth potential from diversified technology and real estate holdings.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Data Center & Digital Infra ETF
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
